Skip to content
thestock.space

On 6 Nov 2026, Gland Pharma was priced at ₹3,169.30, or 42.3× trailing earnings, against an industry P/E of 28.7×. Its ROCE of 14% is the second-lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales and net profit grew 21% and 9.6% a year over 3 years. It has almost no debt, and its dividend yield is 0.6%. It is a mid-cap company with a market cap of ₹52,297 Cr, ranked 14th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 65% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹3,150.00
Day high
₹3,183.40
Day low
₹3,133.20
Prev. close
₹3,145.20
Volume
3.5 L

Health check

2 good · 2 fair · 2 to check
  • ReturnsAhead

    +64.5% over a year, better than 6 of 7 peers.

  • Price tagPricier

    P/E 42.3 vs industry 28.7.

  • GrowthSteady

    Sales +21.2%, profit +9.6% a year over 3 years.

  • ProfitabilityAverage

    ROCE 13.7% vs peer median 17.9%.

  • Balance sheetSolid

    Practically debt-free, Piotroski 9 of 9.

  • Red flags1 to check

    Promoter stake down from 51.8% to 45.8%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Mid cap

₹52,297 Cr, #14 of 154 in its industry by size.

Defensive

Beta 0.52 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹6,725 Cr · profit ₹1,129 Cr
Market cap
₹52,297 Cr
Mid cap
P/E
42.3
Industry 28.7
Price to book
5.04
Peers 4.99
Dividend yield
0.63%
ROE
10.5%
Peers 14.7%
ROCE
13.7%
Peers 17.9%
Debt to equity
0.03
Debt ₹284 Cr
EPS (TTM)
₹74.95
Face value ₹1
OPM (TTM)
26.8%
Net margin 16.8%
Sales growth
+19.6%
Latest quarter vs a year ago
Profit growth
+47.1%
Latest quarter vs a year ago
Price to sales
7.78
EV/EBITDA 28.6

Strengths and risks

Strengths

  • Practically debt-free.
  • Quarterly profit up 47.1% on a year ago.
  • Quarterly sales up 19.6% on a year ago.
  • Positive operating cash flow in each of the last 4 years.

Risks to check

  • Promoter stake down from 51.8% to 45.8%.

Derived automatically from reported figures. Not a recommendation.

About Gland Pharma

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic…

Headquarters
Hyderabad
Employees
4,332
Sector
Healthcare
ISIN
INE068V01023
Website
glandpharma.com

Price range

52 weeks

₹1,573.60₹3,208.60

Today

₹3,133.20₹3,183.40
Avg volume (3M)
6.2 L
1-year return
plus 64.5%
From 52-week high
minus 1.2%

Analyst consensus

14 analysts
BuyMean target ₹3,021.86 minus 4.7%

The mean target is below today’s price.

Target range, with today’s price

Low ₹1,940.00High ₹3,800.00

Next results expected around 27 Jan 2027

Consensus from Yahoo Finance. Not a recommendation.

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
GLANDGland Pharma3,169.30plus 0.77%52,29742.35.0413.7%10.5%26.8%21.2%9.6%0.63%plus 64.5%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrMar 25Jun 25Dec 25Mar 26Jun 26
1,4251,5061,6951,7431,800
–––+22.3%+19.6%
1,0771,1381,2601,2301,311
348368435513489
24.4%24.4%25.7%29.4%27.2%
4457.563.211161.2
7.511.53.9104.4
95.8101108109111
––−24.3––
288313362506435
35.3%31.1%27.8%27.5%27.1%
187215261367317
–––+96.6%+47.1%
11.3213.0815.8722.2319.22

Sep 25 not reported by the data source.

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+21.2%
Profit CAGR 3Y
+9.6%
EPS CAGR 3Y
+9.5%
ROE
10.5%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
3,5925,6425,5846,403
–+57.1%minus 1.0%+14.7%
2,5754,3014,3164,773
1,0171,3411,2681,630
28.3%23.8%22.7%25.5%
236162208309
6.321.837.429.6
147345378424
−45.7−3.92.3−21.5
1,0551,1331,0631,465
25.9%31.8%34.3%29.9%
7817726991,027
–minus 1.1%minus 9.6%+47.1%
47.4346.8942.4062.28

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
16.516.516.516.5
7,9428,7079,13410,341
4.5372314284
8141,5651,7601,869
8,77810,66111,22512,511
1,7993,8713,9754,474
240279182384
–655––
3,7631,9392,9523,359
2,9753,9184,1164,294
8,77810,66111,22512,511

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
3649979151,031
1,208−1,7571,705138
14.9−799−433−417
1,587−1,5602,186752
−223−398−394−494
141599521537
––−329−297

Shareholding pattern

Source: NSE filings
45.8%
promoters
  • Promoters45.75%
  • Public54.25%
  • As of 30 Sep 2026
QuarterSplitPromotersPublicPromoter change
30 Sep 202645.75%54.25%minus 6.02
30 Jun 202651.77%48.23%minus 0.06
31 Mar 202651.83%48.17%0.00
31 Dec 202551.83%48.17%0.00
30 Sep 202551.83%48.17%–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you